First Trust Advisors LP Has $2.04 Million Stake in Allscripts Healthcare Solutions Inc (MDRX)

First Trust Advisors LP raised its stake in Allscripts Healthcare Solutions Inc (NASDAQ:MDRX) by 129.5% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 143,024 shares of the software maker’s stock after acquiring an additional 80,698 shares during the quarter. First Trust Advisors LP owned approximately 0.08% of Allscripts Healthcare Solutions worth $2,038,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Avestar Capital LLC grew its position in shares of Allscripts Healthcare Solutions by 24.1% in the third quarter. Avestar Capital LLC now owns 20,051 shares of the software maker’s stock valued at $270,000 after purchasing an additional 3,899 shares during the period. Mutual of America Capital Management LLC grew its position in shares of Allscripts Healthcare Solutions by 3.0% in the second quarter. Mutual of America Capital Management LLC now owns 152,677 shares of the software maker’s stock valued at $1,832,000 after purchasing an additional 4,442 shares during the period. Summit Trail Advisors LLC purchased a new stake in shares of Allscripts Healthcare Solutions in the second quarter valued at $105,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Allscripts Healthcare Solutions in the second quarter valued at $160,000. Finally, Los Angeles Capital Management & Equity Research Inc. grew its position in shares of Allscripts Healthcare Solutions by 28.0% in the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 61,095 shares of the software maker’s stock valued at $733,000 after purchasing an additional 13,360 shares during the period.

In other news, EVP Brian Farley sold 6,000 shares of the company’s stock in a transaction dated Friday, September 14th. The stock was sold at an average price of $14.67, for a total value of $88,020.00. Following the completion of the sale, the executive vice president now owns 242,673 shares of the company’s stock, valued at $3,560,012.91. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.75% of the stock is currently owned by insiders.

MDRX stock opened at $10.21 on Monday. Allscripts Healthcare Solutions Inc has a 12-month low of $9.41 and a 12-month high of $16.13. The company has a quick ratio of 0.94, a current ratio of 0.94 and a debt-to-equity ratio of 1.61. The stock has a market cap of $1.78 billion, a price-to-earnings ratio of 21.72, a PEG ratio of 1.43 and a beta of 1.34.

Allscripts Healthcare Solutions (NASDAQ:MDRX) last posted its quarterly earnings results on Thursday, November 1st. The software maker reported $0.13 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.14 by ($0.01). Allscripts Healthcare Solutions had a negative net margin of 0.25% and a positive return on equity of 8.25%. The firm had revenue of $536.00 million for the quarter, compared to analysts’ expectations of $546.09 million. During the same period last year, the firm posted $0.15 EPS. Allscripts Healthcare Solutions’s revenue was up 18.8% on a year-over-year basis. On average, research analysts anticipate that Allscripts Healthcare Solutions Inc will post 0.54 earnings per share for the current year.

A number of brokerages have recently commented on MDRX. Zacks Investment Research raised Allscripts Healthcare Solutions from a “sell” rating to a “hold” rating in a research report on Friday. BidaskClub raised Allscripts Healthcare Solutions from a “sell” rating to a “hold” rating in a research report on Tuesday, November 27th. Argus downgraded Allscripts Healthcare Solutions from a “buy” rating to a “hold” rating in a research report on Wednesday, November 14th. ValuEngine downgraded Allscripts Healthcare Solutions from a “hold” rating to a “sell” rating in a research report on Friday, November 2nd. Finally, Robert W. Baird lowered their price target on Allscripts Healthcare Solutions from $16.00 to $14.00 and set an “outperform” rating for the company in a research report on Friday, November 2nd. One research analyst has rated the stock with a sell rating, six have given a hold rating and eight have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $15.51.

ILLEGAL ACTIVITY NOTICE: “First Trust Advisors LP Has $2.04 Million Stake in Allscripts Healthcare Solutions Inc (MDRX)” was originally published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The legal version of this report can be accessed at https://www.americanbankingnews.com/2018/12/03/first-trust-advisors-lp-has-2-04-million-stake-in-allscripts-healthcare-solutions-inc-mdrx.html.

About Allscripts Healthcare Solutions

Allscripts Healthcare Solutions, Inc provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records, connectivity, private cloud hosting, outsourcing, analytics, patient engagement, clinical decision support, and population health management solutions.

Featured Story: Stock Symbols and CUSIP Explained

Want to see what other hedge funds are holding MDRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allscripts Healthcare Solutions Inc (NASDAQ:MDRX).

Institutional Ownership by Quarter for Allscripts Healthcare Solutions (NASDAQ:MDRX)

Receive News & Ratings for Allscripts Healthcare Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allscripts Healthcare Solutions and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply